Drug Trial Radar · NCT06247605
A Phase IIII Study of AL8326 in Small Cell Lung Cancer
Last checked: Nov 19, 2026Latest source record: Feb 8, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
243
Planned (sponsor's estimate)
Start
Oct 26, 2023
Primary completion
Jul 2028
Study completion Jul 2029
Sponsor
- Lead sponsor
- Advenchen Laboratories Nanjing Ltd.Industry
- Sponsor type
- Industry
- First posted
- Feb 8, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, randomized, double-blind, placebo-controlled, phase III study to evaluate the efficacy and safety of AL8326 tablets in small cell lung cancer (SCLC) patients with disease progression or recurrence after receiving at least second-line treatment regimens.
Conditions
- Small Cell Lung Carcinoma
Interventions
AL8326 tabletsDrug
10mg/tablet, Oral administration, once daily.
placeboDrug
Oral administration, once daily.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall survival (OS)Time frame: Cycle 1 Day 1 up to 3 years (each cycle is 28 days)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
JILIN Cancer Hospital
Changchun, Jilin, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.